Zobrazeno 1 - 10
of 55
pro vyhledávání: ''
Autor:
Richard Greil, Armin Gerger, Renate Schaberl-Moser, Martin Pichler, Dominik A. Barth, Michael Stotz, Angela Djanani, Antonia Gantschnigg, Lena Horvath, Jakob M. Riedl, Herbert Stöger, Felix Renneberg, Konstantin Schlick, Christopher Rossmann, Florian Posch, Esther Schwarzenbacher, Florian Moik
Publikováno v:
European Journal of Cancer. 151:3-13
Background Gemcitabine/nab-paclitaxel (GN) and FOLFIRINOX are standard first-line treatment options for advanced pancreatic ductal adenocarcinoma (aPDAC), but currently no prospective randomised head-to-head comparison between these treatments has ye
Autor:
Toshihide Yokoyama, Takashi Yokoi, Satoru Miura, Shunsuke Teraoka, Shuji Murakami, Kazushige Wakuda, Yuko Oya, Motohiro Tamiya, Atsushi Nakamura, Takaaki Tokito, Keisuke Tomii, Kenichi Yoshimura, O. Yamaguchi, Nobuyuki Yamamoto, Satoshi Watanabe, Hiroshige Yoshioka, Tetsuhiko Asao, Shoichi Itoh, D. Fujimoto, Akihiro Tamiya, Hiroshi Yokouchi, Koji Haratani
Publikováno v:
European Journal of Cancer. 150:63-72
Introduction Despite the extensive use of the combination of cytotoxic chemotherapy and programmed cell death protein 1/programmed death-ligand 1 checkpoint inhibitors for cancer treatment, the incidence and characteristics of pneumonitis caused by t
Autor:
Bart A. van de Wiel, Judith M. Versluis, Robyn P. M. Saw, Sydney Ch'ng, C. Blank, Bastian Schilling, Irene L.M. Reijers, Richard A. Scolyer, Georgina V. Long, Michel W.J.M. Wouters, Alexander C.J. van Akkooi, Elisa A. Rozeman, Alexander M. Menzies
Publikováno v:
European Journal of Cancer. 148:51-57
Background Patients with synchronous clinical stage III melanoma can present with primary melanoma lesions, locally recurrent melanoma or in-transit metastases. Neoadjuvant ipilimumab plus nivolumab induces high pathologic response rates and an impre
Autor:
Aileen Deng, Jordan M. Winter, Charles J. Yeo, Chun Wang, Atrayee Basu Mallick, Steven J. Cohen, James Posey
Publikováno v:
European Journal of Cancer. 147:17-28
To compare overall survival (OS) in patients who underwent surgery for early-stage pancreatic adenocarcinoma (rPca) based on sequence (NAT, neoadjuvant therapy and/or AT, adjuvant therapy) and type (SA, single-agent or MA, multi-agent) of chemotherap
Autor:
Toshihide Yokoyama, D. Fujimoto, Takuya Aoki, Takashi Yokoi, Kensuke Suzuki, Kazuhiko Nakagawa, Akihiro Bessho, Ken Maeno, Kazumi Nishino, Takashi Seto, Koji Azuma, Satoshi Watanabe, Nobuyuki Yamamoto, Hiroaki Akamatsu, Osamu Hataji, Shinya Sakata, Hidetoshi Hayashi, Motoyasu Okuno, Takeharu Yamanaka, Toshiyuki Kozuki, Yoshihiro Hattori, Tomoya Fukui, Kentaro Tanaka, Atsushi Nakamura, Akihito Kubo, Katsuya Hirano, Koichi Azuma, Haruko Daga, Atsuhisa Tamura, Masahide Mori, Satoru Miura, Shigeto Hontsu, Yuko Oya, Kentaro Ito, Haruki Kobayashi
Publikováno v:
European Journal of Cancer. 145:183-193
Background The data of sequential therapy of anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) in clinical practice have been limited. Methods We reviewed the clinical data of patients with ALK-rearranged non-small cell lung cancer w
Autor:
Yasuo Nakai, Takeo Maekawa, Hiroyuki Irie, Yasuhiro Fujisawa, Kanako Matsuyama, Hiroshi Uchi, Shigeto Matsushita, Ikko Muto, Yuki Yamamoto, Hiroshi Kato, Yoshiyuki Nakamura, Masahito Yasuda, Tatsuya Kaji, Jiro Uehara, Koji Yoshino, Taku Fujimura, Jun Asai, Takamichi Ito
Publikováno v:
European Journal of Cancer. 145:210-220
Background As most clinical trials evaluating BRAF and MEK inhibitor combination therapy (B + Minh) have been conducted in Western countries, little is known about the effect of B + Minh among East Asian populations. Material and methods Data from pa
Autor:
Bella Pajares, Sofia Ruiz-Medina, Enrique Saez, Antonia Márquez, Laura Galvez, Begoña Jimenez, Ana Godoy, Pablo Rodriguez-Brazzarola, Maria E. Dominguez-Recio, Francisco Carabantes, Alfonso Sánchez-Muñoz, María José Bermejo, Irene López, José M. Jerez, Tamara Diaz-Redondo, Ester Villar, Héctor Mesa, Leo Franco, Nuria Ribelles, Emilio Alba
Publikováno v:
European Journal of Cancer. 144:224-231
Background CDK4/6 inhibitors plus endocrine therapies are the current standard of care in the first-line treatment of HR+/HER2-negative metastatic breast cancer, but there are no well-established clinical or molecular predictive factors for patient r
Autor:
Richard M. Goldberg, Pierre Laurent-Puig, Thomas C. Smyrk, Julien Taieb, Aziz Zaanan, Karine Le Malicot, Gunnar Folprecht, Jean-Luc Van Laethem, Qian Shi, Steven R. Alberts, Josep Tabernero, Enrico Mini, Luke Huebner, Sakti Chakrabarti, Frank A. Sinicrope
Publikováno v:
Eur J Cancer
BACKGROUND: Stratification of patients with stage III colon cancer into low (T(1–3)N(1)) and high (T(4) and/or N(2)) risk groups is used to guide the duration of adjuvant chemotherapy. We determined the relative contribution of clinical and molecul
Autor:
Marco Maria Germani, Alessandra Boccaccino, Giuseppe Aprile, Chiara Cremolini, Salvatore Corallo, Filippo Pietrantonio, Daniele Rossini, Umberto Cillo, Giovanni Centonze, Massimo Milione, Alfredo Falcone, Roberto Moretto, Sara Lonardi, Antonino Belfiore, Michele Prisciandaro, Gabriella Fontanini, Filippo de Braud, Lucio Urbani, Fotios Loupakis, Laura Cattaneo, Federica Morano, Luca Morelli, Silvia Brich, Matteo Fassan, Federica Marmorino
Publikováno v:
European Journal of Cancer. 135:78-88
Immune-contexture of tumour microenvironment (TME) influences prognosis of colorectal cancer (CRC) patients and can be altered by cytotoxic and targeted agents. Limited data are available regarding the immune-TME of CRC after treatment.An extensive i
Autor:
Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v:
European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in